Results

Total Results: 1,528 records

Showing results for "drugs".

241. Alcohol-misuse-drug-therapy-140326 (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/alcohol-misuse-drug-therapy_research-protocol.pdf
     January 27, 2012 - prevention or pharmacotherapy combined with various co-interventions (including both FDA-approved drugs … Inpatient settings Interventions As defined above in PICOTS Pharmacotherapy for alcohol withdrawal; any drugs … J Stud Alcohol Drugs. 2008 Jul;69(4):535-8. PMID: 18612569. 23.

242. Disposition of Comments Report for Stroke Prevention in Atrial Fibrillation (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/stroke-atrial-fibrillation_disposition-comments.pdf
     August 23, 2013 - Public Reviewer #1 – Sabine Luik, Boehringer Ingelheim Pharmaceuticals, Inc. … Public Reviewer #1 – Sabine Luik, Boehringer Ingelheim Pharmaceuticals, Inc. … Public Reviewer #1 – Sabine Luik, Boehringer Ingelheim Pharmaceuticals, Inc. … Acknowledged Public Reviewer #1 – Sabine Luik, Boehringer Ingelheim Pharmaceuticals, Inc. … No known reversibility agents for the new drugs. Thank you for this comment.

243. Effective Health Care (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/TND_0075_03-10-2009.pdf
     January 01, 2009 - corticosteroids, immune system suppressors, antibiotics, anti-diarrheals, anti-tumor necrosis factor (TNF) drugs

244. Effective Health Care (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/TND_0313_02-09-2009.pdf
     January 01, 2009 - A number of drugs and dietary measures have been shown to reduce the rate of stone recurrence.

245. S16 (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/s16.pdf
     October 01, 2007 - controlled trials (RCTs) remain the ac- cepted “gold standard” for determining the efficacy of new drugs … Follow-up and monitoring is designed to promote adherence to the drugs under study and to detect any … Drug coverage—Which bisphosphonate drugs should be included on a drug fomulary? … , quality of intervention Timing of intervention Cointerventions, quality of care Adherence (for drugs … Treatment with drugs to lower blood pressure and blood cholesterol based on an individual’s absolute

246. S89 (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/s89.pdf
     October 01, 2007 - Rapid Cycle Analysis Team Background: Rare but serious adverse events associated with vac- cines or drugs … meningococcal vaccine, drug safety (Med Care 2007;45: S89–S95) Concerns about the safety of vaccines and drugs … the Centers for Disease Control and Prevention (CDC) and Food and Drug Administration (FDA) and, for drugs … In addition, because drugs treat specific conditions, the pool of users for a new medication is limited … early detection of potential adverse events after the introduction of new vaccines, and possibly new drugs

247. Evidence Report on the (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/rheumatoid-arthritis-medicine_research-protocol.pdf
     December 06, 2010 - Available therapies for RA include corticosteroids, oral disease-modifying antirheumatic drugs (DMARDs … Finally, very little is known about the benefits or risks of these drugs AMONG different patient subgroups … review did not include certolizumab pegol, golimumab, and tocilizumab (listed above), because these drugs … Golimumab Simponi® Tocililizumab Actemra®, RoActemrai® • Comparators: For all KQs: all review drugs

248. Management of Insomnia Disorder in Adults: Current State of the Evidence (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/insomnia_clinician.pdf
     August 01, 2017 - Food and Drug Administration (FDA) has approved several prescription drugs for insomnia, typically … Food and Drug Administration (FDA) for insomnia. d Other benzodiazepines include drugs approved by … the FDA for insomnia (estazolam, flurazepam, lorazepam, quazepam, and triazolam) and drugs not approved

249. Layout 1 (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/cancer-anemia_executive.pdf
     May 01, 2006 - trials comparing darbepoetin to epoetin showed no statistically significant difference between these drugs … trials comparing darbepoetin to epoetin showed no statistically significant difference between these drugs … trials comparing darbepoetin to epoetin showed no statistically significant difference between these drugs

250. Effective Health Care (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/TND_0108_05-24-2009.pdf
     January 01, 2009 - migraine patients require multiple doses and often do not relieve the migraine and that some other drugs

251. Treatments for Basal Cell and Squamous Cell Carcinoma of the Skin - Executive Summary (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/evidence-summary-cer-199-skin-cancer.pdf
     December 01, 2017 - • Recurrence rates for SCC in situ were lower with PDT and cryotherapy than with drugs. … Adverse Events, All BCC Lesions In Table B drugs were most likely to have adverse events leading to … Conversely, use of topical drugs is generally limited to primary, superficial tumors. … Therefore, comparisons of the efficacy of radiation and drugs for the low-risk BCCs included in our … Adjuvant radiotherapy and new drugs (including epidermal growth factor receptor inhibitors, such as

252. Untitled (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/heart-disease-ace-inhibitor-arb_surveillance.pdf
     July 06, 2015 - Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324 … The primary goal of this review is to identify any missing studies, drugs, interventions, or devices … is needed to determine if ACE inhibitors or ARBs offer additional benefits over other vasoactive drugs … Since ONTARGET directly compared the same drugs as were evaluated in the placebo-controlled HOPE and … Since ONTARGET directly compared the same drugs as were evaluated in the placebo- controlled HOPE and

253. Layout 1 (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/antidepressants-2007_executive.pdf
     January 01, 2007 - Both drugs are produced by the same manufacturer, which funded all available studies. … The second- generation antidepressants cannot be considered identical drugs. … Evidence of moderate strength supports some differences among individual drugs with respect to onset … The incidence was 8-percent (95-percent CI, 3-11 percent) higher than with comparator drugs. … Mirtazapine led to higher weight gains than comparator drugs (fluoxetine, paroxetine, venlafaxine, and

254. Disposition of Comments Report for Acute Migraine Treatment in Emergency Settings (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/migraine-emergency_disposition-comments.pdf
     November 27, 2012 - We understand that many drugs have different mechanisms of action (e.g., an antiemetic can have analgesic … Promethazine (Phenergan) was included in Table 1 under the “other agents” portion as one of the drugs … Peer Reviewer #2 Executive summary In the Executive Summary, drugs are loosely discussed in terms … of neuroleptics, metoclopramide, and antihistamines (without specific drugs listed), while in the … We collectively referred to these drugs as “orphan agents”.

255. 8 (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/methods-guidance-harms_methods.pdf
     November 01, 2008 - most regulatory approvals, and the source of most advertising and other claims made on behalf of drugs … For example, a systematic review of nonsteroidal anti-inflammatory drugs (NSAIDs) found cyclo-oxygenase … Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs … Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis … Causality assessment of adverse reactions to drugs—I.

256. 8 (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/methodsguide_chou_assessing_harms_when_comparing.pdf
     November 01, 2008 - most regulatory approvals, and the source of most advertising and other claims made on behalf of drugs … For example, a systematic review of nonsteroidal anti-inflammatory drugs (NSAIDs) found cyclo-oxygenase … Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs … Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis … Causality assessment of adverse reactions to drugs—I.

257. Juvenile-Arthritis-Dmards Surveillance (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/related_files/juvenile-arthritis-dmards_surveillance.pdf
     March 14, 2013 - CER # 28: Disease-Modifying Antirheumatic Drugs (DMARDs) in Children with Juvenile Idiopathic Arthritis … ..................................................... 5 1 Disease-Modifying Antirheumatic Drugs … Introduction Comparative Effectiveness Review (CER) #28, Disease-Modifying Antirheumatic Drugs … examples of how advances in understanding the biology of inflammation have led to development of drugs … Disease-Modifying Antirheumatic Drugs (DMARDs) in Children with Juvenile Idiopathic Arthritis (JIA)

258. Juvenile-Arthritis-Dmards Surveillance (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/juvenile-arthritis-dmards_surveillance.pdf
     March 14, 2013 - CER # 28: Disease-Modifying Antirheumatic Drugs (DMARDs) in Children with Juvenile Idiopathic Arthritis … ..................................................... 5 1 Disease-Modifying Antirheumatic Drugs … Introduction Comparative Effectiveness Review (CER) #28, Disease-Modifying Antirheumatic Drugs … examples of how advances in understanding the biology of inflammation have led to development of drugs … Disease-Modifying Antirheumatic Drugs (DMARDs) in Children with Juvenile Idiopathic Arthritis (JIA)

259. Research Protocol: Diabetes Medications for Adults With Type 2 Diabetes: An Update Focused on Monotherapy and Add-On Therapy to Metformin (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/diabetes-update-2015_research-protocol.pdf
     January 01, 2015 - have also emerged since 2010 which may change the balance of benefit and risk attributable to these drugs … In this era of intensive direct-to-consumer marketing of new drugs, clinicians need a trustworthy source … Health and Human Services; 2008 [cited 2014 July 13]; Available from: http://www.fda.gov/downloads/Drugs … Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs … http:www.effectivehealthcare.ahrq.gov http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation

260. Methods-Guidance-Applicability Methods (pdf file)
     effectivehealthcare.ahrq.gov/sites/default/files/pdf/methods-guidance-applicability_methods.pdf
     January 01, 2011 - For example, the individual trials of statin drugs to treat high cholesterol each selected specific … and discrete populations, used different drugs, different dosages, and different cointerventions. … differing risks, nationalities, and underlying conditions provides evidence that the benefits of statin drugs … Drugs 2007;67(14):1969-1979. 20. Walker, CF, Kordas K, Stoltzfus, RJ, et al. … Drug class review of Alzheimer’s drugs. Final report. 2006.